Various Cancer Types
EAY191 / ComboMATCH
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
STATUS: Active
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
- Patient must have measurable disease
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50%
- Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
- All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
- Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria: * Patients must have progressed on at least one line of standard systemic therapy OR * Patients whose disease has no standard treatment that has been shown to prolong overall survival
- Patient must meet one of the following requirements: * Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR * Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria: ** Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial ** Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response [CR] or partial response [PR]) to any intervening therapy after collection of the tissue ** Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR * Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria: ** Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available * NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions. Performance of the mandatory research biopsy or submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only
- NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial
United States
AL
Birmingham
University of Alabama at Birmingham Cancer Center
Contact: Site Public Contact
Email: tmyrick@uab.edu
Mobile
University of South Alabama Mitchell Cancer Institute
Contact: Site Public Contact
Email: pfrancisco@usouthal.edu
AZ
Goodyear
CTCA at Western Regional Medical Center
Contact: Site Public Contact
Kingman
Kingman Regional Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Phoenix
Mayo Clinic Hospital in Arizona
Contact: Site Public Contact
CA
Arroyo Grande
PCR Oncology
Contact: Site Public Contact
Email: research@sncrf.org
Carmichael
Mercy Cancer Center - Carmichael
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
Mercy San Juan Medical Center
Contact: Site Public Contact
Email: OncologyResearch@DignityHealth.org
Dublin
Epic Care-Dublin
Contact: Site Public Contact
Elk Grove
Mercy Cancer Center - Elk Grove
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
Martinez
Contra Costa Regional Medical Center
Contact: Site Public Contact
Orange
Saint Joseph Hospital - Orange
Contact: Site Public Contact
Palo Alto
Stanford Cancer Institute Palo Alto
Contact: Site Public Contact
Email: ccto-office@stanford.edu
VA Palo Alto Health Care System
Contact: Site Public Contact
Rocklin
Mercy Cancer Center - Rocklin
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
Sacramento
Mercy Cancer Center - Sacramento
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
San Diego
Sharp Memorial Hospital
Contact: Site Public Contact
Email: cathy.wood@sharp.com
San Francisco
UCSF Medical Center-Mission Bay
Contact: Site Public Contact
Email: cancertrials@ucsf.edu
Santa Monica
Saint John's Cancer Institute
Contact: Site Public Contact
Walnut Creek
Epic Care Cyberknife Center
Contact: Site Public Contact
Email: somega@bati.org
Whittier
Presbyterian Intercommunity Hospital
Contact: Site Public Contact
Woodland
Woodland Memorial Hospital
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
CO
Aurora
UCHealth University of Colorado Hospital
Contact: Site Public Contact
Fort Collins
Cancer Care and Hematology-Fort Collins
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu
Poudre Valley Hospital
Contact: Site Public Contact
Greeley
UCHealth Greeley Hospital
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu
Loveland
Medical Center of the Rockies
Contact: Site Public Contact
DE
Newark
Helen F Graham Cancer Center
Contact: Site Public Contact
Email: lbarone@christianacare.org
Medical Oncology Hematology Consultants PA
Contact: Site Public Contact
Email: lbarone@christianacare.org
FL
Aventura
UM Sylvester Comprehensive Cancer Center at Aventura
Contact: Site Public Contact
Coral Gables
UM Sylvester Comprehensive Cancer Center at Coral Gables
Contact: Site Public Contact
Deerfield Beach
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Contact: Site Public Contact
Fort Lauderdale
Broward Health Medical Center
Contact: Site Public Contact
Email: Allison.bruce@nemours.org
Gainesville
University of Florida Health Science Center - Gainesville
Contact: Site Public Contact
Email: cancer-center@ufl.edu
Jacksonville
Mayo Clinic in Florida
Contact: Site Public Contact
Miami
UM Sylvester Comprehensive Cancer Center at Kendall
Contact: Site Public Contact
University of Miami Miller School of Medicine-Sylvester Cancer Center
Contact: Site Public Contact
Plantation
UM Sylvester Comprehensive Cancer Center at Plantation
Contact: Site Public Contact
GA
Newnan
CTCA at Southeastern Regional Medical Center
Contact: Site Public Contact
HI
Aiea
Hawaii Cancer Care - Westridge
Contact: Site Public Contact
Email: info@hawaiicancercare.com
Pali Momi Medical Center
Contact: Site Public Contact
Ewa Beach
The Queen's Medical Center - West Oahu
Contact: Site Public Contact
Email: rohta@queens.org
Honolulu
Hawaii Cancer Care Inc - Waterfront Plaza
Contact: Site Public Contact
Email: i.webster@hawaiicancercare.com
Kapiolani Medical Center for Women and Children
Contact: Site Public Contact
Queen's Cancer Cenrer - POB I
Contact: Site Public Contact
Queen's Cancer Center - Kuakini
Contact: Site Public Contact
Queen's Medical Center
Contact: Site Public Contact
Straub Clinic and Hospital
Contact: Site Public Contact
IA
Ankeny
Mission Cancer and Blood - Ankeny
Contact: Site Public Contact
Cedar Rapids
Mercy Hospital
Contact: Site Public Contact
Oncology Associates at Mercy Medical Center
Contact: Site Public Contact
Des Moines
Mercy Medical Center - Des Moines
Contact: Site Public Contact
Email: cancerresearch@mercydesmoines.org
Mission Cancer and Blood - Des Moines
Contact: Site Public Contact
ID
Boise
Saint Alphonsus Cancer Care Center-Boise
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saint Luke's Cancer Institute - Boise
Contact: Site Public Contact
Email: eslinget@slhs.org
Caldwell
Saint Alphonsus Cancer Care Center-Caldwell
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Coeur D'Alene
Kootenai Health - Coeur d'Alene
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Fruitland
Saint Luke's Cancer Institute - Fruitland
Contact: Site Public Contact
Email: eslinget@slhs.org
Meridian
Saint Luke's Cancer Institute - Meridian
Contact: Site Public Contact
Email: eslinget@slhs.org
Nampa
Saint Alphonsus Cancer Care Center-Nampa
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Saint Luke's Cancer Institute - Nampa
Contact: Site Public Contact
Email: eslinget@slhs.org
Post Falls
Kootenai Clinic Cancer Services - Post Falls
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Sandpoint
Kootenai Clinic Cancer Services - Sandpoint
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Twin Falls
Saint Luke's Cancer Institute - Twin Falls
Contact: Site Public Contact
Email: eslinget@slhs.org
IL
Barrington
Advocate Good Shepherd Hospital
Contact: Site Public Contact
Bloomington
Illinois CancerCare-Bloomington
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Canton
Illinois CancerCare-Canton
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Carthage
Illinois CancerCare-Carthage
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Centralia
Centralia Oncology Clinic
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Chicago
Advocate Illinois Masonic Medical Center
Contact: Site Public Contact
John H Stroger Jr Hospital of Cook County
Contact: Site Public Contact
Northwestern University
Contact: Site Public Contact
Email: cancer@northwestern.edu
University of Chicago Comprehensive Cancer Center
Contact: Site Public Contact
Email: cancerclinicaltrials@bsd.uchicago.edu
Crystal Lake
AMG Crystal Lake - Oncology
Contact: Site Public Contact
Email: advocateresearch@advocate.com
Danville
Carle at The Riverfront
Contact: Site Public Contact
Email: Research@Carle.com
DeKalb
Northwestern Medicine Cancer Center Kishwaukee
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Decatur
Cancer Care Specialists of Illinois - Decatur
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Decatur Memorial Hospital
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Dixon
Illinois CancerCare-Dixon
Contact: Site Public Contact
Downers Grove
Advocate Good Samaritan Hospital
Contact: Site Public Contact
Email: Barbara.barhamand@advocatehealth.com
Effingham
Carle Physician Group-Effingham
Contact: Site Public Contact
Email: Research@carle.com
Crossroads Cancer Center
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Elgin
Advocate Sherman Hospital
Contact: Site Public Contact
Eureka
Illinois CancerCare-Eureka
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Galesburg
Illinois CancerCare-Galesburg
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Geneva
Northwestern Medicine Cancer Center Delnor
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Harvey
Ingalls Memorial Hospital
Contact: Site Public Contact
Email: clinicaltrials@ingalls.org
Hazel Crest
Advocate South Suburban Hospital
Contact: Site Public Contact
Kewanee
Illinois CancerCare-Kewanee Clinic
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Lake Forest
Northwestern Medicine Lake Forest Hospital
Contact: Site Public Contact
Email: cancertrials@northwestern.edu
Libertyville
AMG Libertyville - Oncology
Contact: Site Public Contact
Email: advocateresearch@advocatehealth.com
Condell Memorial Hospital
Contact: Site Public Contact
Email: advocateresearch@advocatehealth.com
Macomb
Illinois CancerCare-Macomb
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Mattoon
Carle Physician Group-Mattoon/Charleston
Contact: Site Public Contact
Email: Research@carle.com
New Lenox
UC Comprehensive Cancer Center at Silver Cross
Contact: Site Public Contact
Email: cancerclinicaltrials@bsd.uchicago.edu
O'Fallon
Cancer Care Center of O'Fallon
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com
Oak Lawn
Advocate Christ Medical Center
Contact: Site Public Contact
Orland Park
Northwestern Medicine Orland Park
Contact: Site Public Contact
Email: nctnprogram_rhlccc@northwestern.edu
University of Chicago Medicine-Orland Park
Contact: Site Public Contact
Email: cancerclinicaltrials@bsd.uchicago.edu
Ottawa
Illinois CancerCare-Ottawa Clinic
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Park Ridge
Advocate Lutheran General Hospital
Contact: Site Public Contact
Pekin
Illinois CancerCare-Pekin
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Peoria
Illinois CancerCare-Peoria
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Peru
Illinois CancerCare-Peru
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Princeton
Illinois CancerCare-Princeton
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Shiloh
Memorial Hospital East
Contact: Site Public Contact
Email: dschwab@wustl.edu
Springfield
Memorial Medical Center
Contact: Site Public Contact
Email: pallante.beth@mhsil.com
Southern Illinois University School of Medicine
Contact: Site Public Contact
Springfield Clinic
Contact: Site Public Contact
Urbana
Carle Cancer Center
Contact: Site Public Contact
Email: Research@carle.com
Warrenville
Northwestern Medicine Cancer Center Warrenville
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Washington
Illinois CancerCare - Washington
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com
Zion
Midwestern Regional Medical Center
Contact: Site Public Contact
IN
Richmond
Reid Health
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
South Bend
Memorial Hospital of South Bend
Contact: Site Public Contact
KY
Lexington
Saint Joseph Hospital East
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
University of Kentucky/Markey Cancer Center
Contact: Site Public Contact
Paducah
Mercy Health - Paducah Cancer Center
Contact: Site Public Contact
Email: BJWarner@mercy.com
LA
New Orleans
Ochsner Medical Center Jefferson
Contact: Site Public Contact
Email: Elisemarie.curry@ochsner.org
MA
Boston
Beth Israel Deaconess Medical Center
Contact: Site Public Contact
Dana-Farber Cancer Institute
Contact: Site Public Contact
Tufts Medical Center
Contact: Site Public Contact
Email: ContactUsCancerCenter@TuftsMedicalCenter.org
Springfield
Baystate Medical Center
Contact: Site Public Contact
Email: tamara.wrenn@baystatehealth.org
MD
Baltimore
University of Maryland/Greenebaum Cancer Center
Contact: Site Public Contact
Bethesda
National Institutes of Health Clinical Center
Contact: Site Public Contact
Cumberland
UPMC Western Maryland
Contact: Site Public Contact
ME
Augusta
Harold Alfond Center for Cancer Care
Contact: Site Public Contact
Brewer
Lafayette Family Cancer Center-EMMC
Contact: Site Public Contact
Scarborough
Maine Medical Center- Scarborough Campus
Contact: Site Public Contact
Email: wrighd@mmc.org
South Portland
Maine Medical Partners - South Portland
Contact: Site Public Contact
Email: ClinicalResearch@mmc.org
MI
Ann Arbor
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Battle Creek
Bronson Battle Creek
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Brighton
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Trinity Health Medical Center - Brighton
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Canton
Trinity Health IHA Medical Group Hematology Oncology - Canton
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Trinity Health Medical Center - Canton
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Chelsea
Chelsea Hospital
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Dearborn
Corewell Health Dearborn Hospital
Contact: Site Public Contact
Farmington Hills
Corewell Health Farmington Hills Hospital
Contact: Site Public Contact
Flint
Genesee Cancer and Blood Disease Treatment Center
Contact: Site Public Contact
Email: wstrong@ghci.org
Genesee Hematology Oncology PC
Contact: Site Public Contact
Email: wstrong@ghci.org
Genesys Hurley Cancer Institute
Contact: Site Public Contact
Email: wstrong@ghci.org
Hurley Medical Center
Contact: Site Public Contact
Email: wstrong@ghci.org
Grand Rapids
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Trinity Health Grand Rapids Hospital
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Kalamazoo
Ascension Borgess Cancer Center
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Borgess Medical Center
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Bronson Methodist Hospital
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
West Michigan Cancer Center
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Lansing
University of Michigan Health - Sparrow Lansing
Contact: Site Public Contact
Email: harsha.trivedi@umhsparrow.org
Livonia
Trinity Health Saint Mary Mercy Livonia Hospital
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Macomb Township
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Contact: Site Public Contact
Email: karen.forman@ascension.org
Muskegon
Trinity Health Muskegon Hospital
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Niles
Corewell Health Lakeland Hospitals - Niles Hospital
Contact: Site Public Contact
Norton Shores
Cancer and Hematology Centers of Western Michigan - Norton Shores
Contact: Site Public Contact
Email: connie.szczepanek@crcwm.org
Pontiac
Michigan Healthcare Professionals Pontiac
Contact: Site Public Contact
Email: Emily.Crofts@trinity-health.org
Trinity Health Saint Joseph Mercy Oakland Hospital
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Reed City
Corewell Health Reed City Hospital
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Royal Oak
Corewell Health Children's
Contact: Site Public Contact
Corewell Health William Beaumont University Hospital
Contact: Site Public Contact
Saginaw
MyMichigan Medical Center Saginaw
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Oncology Hematology Associates of Saginaw Valley PC
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Saint Joseph
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Tawas City
MyMichigan Medical Center Tawas
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Traverse City
Munson Medical Center
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Troy
Corewell Health Beaumont Troy Hospital
Contact: Site Public Contact
West Branch
Saint Mary's Oncology/Hematology Associates of West Branch
Contact: Site Public Contact
Email: lori.srebinski@ascension.org
Wyoming
University of Michigan Health - West
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org
Ypsilanti
Huron Gastroenterology PC
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Contact: Site Public Contact
Email: MCRCwebsitecontactform@stjoeshealth.org
MN
Bemidji
Sanford Joe Lueken Cancer Center
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Coon Rapids
Mercy Hospital
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Deer River
Essentia Health - Deer River Clinic
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org
Duluth
Essentia Health Cancer Center
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org
Edina
Fairview Southdale Hospital
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Hibbing
Essentia Health Hibbing Clinic
Contact: Site Public Contact
Maple Grove
Fairview Clinics and Surgery Center Maple Grove
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Maplewood
Saint John's Hospital - Healtheast
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Minneapolis
Abbott-Northwestern Hospital
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Rochester
Mayo Clinic in Rochester
Contact: Site Public Contact
Saint Louis Park
Park Nicollet Clinic - Saint Louis Park
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Saint Paul
Regions Hospital
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
United Hospital
Contact: Site Public Contact
Email: mmcorc@healthpartners.com
Sandstone
Essentia Health Sandstone
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org
Virginia
Essentia Health Virginia Clinic
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org
MO
Cape Girardeau
Saint Francis Medical Center
Contact: Site Public Contact
Email: sfmc@sfmc.net
Chesterfield
Saint Luke's Hospital
Contact: Site Public Contact
Creve Coeur
Siteman Cancer Center at West County Hospital
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Farmington
Parkland Health Center - Farmington
Contact: Site Public Contact
Saint Louis
Mercy Hospital Saint Louis
Contact: Site Public Contact
Missouri Baptist Medical Center
Contact: Site Public Contact
Siteman Cancer Center at Christian Hospital
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Siteman Cancer Center-South County
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Washington University School of Medicine
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Saint Peters
Siteman Cancer Center at Saint Peters Hospital
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Sainte Genevieve
Sainte Genevieve County Memorial Hospital
Contact: Site Public Contact
Springfield
Mercy Hospital Springfield
Contact: Site Public Contact
Sullivan
Missouri Baptist Sullivan Hospital
Contact: Site Public Contact
Sunset Hills
BJC Outpatient Center at Sunset Hills
Contact: Site Public Contact
MS
Gulfport
Gulfport Memorial Hospital
Contact: Site Public Contact
Email: emede1@lsuhsc.edu
MT
Anaconda
Community Hospital of Anaconda
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Billings
Billings Clinic Cancer Center
Contact: Site Public Contact
Email: research@billingsclinic.org
Bozeman
Bozeman Health Deaconess Hospital
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Great Falls
Benefis Sletten Cancer Institute
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Kalispell
Kalispell Regional Medical Center
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Missoula
Community Medical Center
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
NC
Clinton
Southeastern Medical Oncology Center-Clinton
Contact: Site Public Contact
Email: jfields@cancersmoc.com
Durham
Duke University Medical Center
Contact: Site Public Contact
Goldsboro
Southeastern Medical Oncology Center-Goldsboro
Contact: Site Public Contact
Email: jfields@cancersmoc.com
Jacksonville
Southeastern Medical Oncology Center-Jacksonville
Contact: Site Public Contact
Email: jfields@cancersmoc.com
Raleigh
Duke Women's Cancer Care Raleigh
Contact: Site Public Contact
ND
Bismarck
Sanford Bismarck Medical Center
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Fargo
Sanford Broadway Medical Center
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
Sanford Roger Maris Cancer Center
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org
NJ
Lakewood
Monmouth Medical Center Southern Campus
Contact: Site Public Contact
Email: mary.danish@rwjbh.org
Long Branch
Monmouth Medical Center
Contact: Site Public Contact
Email: mary.danish@rwjbh.org
Middletown
Memorial Sloan Kettering Monmouth
Contact: Site Public Contact
New Brunswick
Rutgers Cancer Institute of New Jersey
Contact: Site Public Contact
Pennington
Capital Health Medical Center-Hopewell
Contact: Site Public Contact
Email: clinicaltrials@capitalhealth.org
Sewell
Sidney Kimmel Cancer Center Washington Township
Contact: Site Public Contact
Email: ONCTrialNow@jefferson.edu
Somerville
Robert Wood Johnson University Hospital Somerset
Contact: Site Public Contact
Email: Siby.Varughese@rwjbh.org
Toms River
Community Medical Center
Contact: Site Public Contact
Email: Lennette.Gonzales@rwjbh.org
NM
Albuquerque
University of New Mexico Cancer Center
Contact: Site Public Contact
Email: HSC-ClinicalTrialInfo@salud.unm.edu
NV
Henderson
OptumCare Cancer Care at Seven Hills
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Charleston
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Fort Apache
Contact: Site Public Contact
Email: research@sncrf.org
Summerlin Hospital Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Reno
Renown Regional Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
NY
Bronx
Montefiore Medical Center - Moses Campus
Contact: Site Public Contact
Email: eskwak@montefiore.org
Montefiore Medical Center-Einstein Campus
Contact: Site Public Contact
Email: eskwak@montefiore.org
Montefiore Medical Center-Weiler Hospital
Contact: Site Public Contact
Email: eskwak@montefiore.org
Buffalo
Roswell Park Cancer Institute
Contact: Site Public Contact
Email: askroswell@roswellpark.org
Commack
Memorial Sloan Kettering Commack
Contact: Site Public Contact
Mineola
NYU Langone Hospital - Long Island
Contact: Site Public Contact
Email: cancertrials@nyulangone.org
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Contact: Site Public Contact
Email: CancerTrials@nyulangone.org
Memorial Sloan Kettering Cancer Center
Contact: Site Public Contact
Mount Sinai Hospital
Contact: Site Public Contact
Email: CCTO@mssm.edu
Rochester
Pluta Cancer Center
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu
Syracuse
State University of New York Upstate Medical University
Contact: Site Public Contact
West Harrison
Memorial Sloan Kettering Westchester
Contact: Site Public Contact
OH
Avon
UH Seidman Cancer Center at UH Avon Health Center
Contact: Site Public Contact
Beachwood
UHHS-Chagrin Highlands Medical Center
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org
Belpre
Strecker Cancer Center-Belpre
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Canton
Aultman Health Foundation
Contact: Site Public Contact
Email: ClinicalReserachDept@aultman.com
Centerville
Miami Valley Hospital South
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Chillicothe
Adena Regional Medical Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Cincinnati
Cincinnati Children's Hospital Medical Center
Contact: Site Public Contact
Email: cancer@cchmc.org
Good Samaritan Hospital - Cincinnati
Contact: Site Public Contact
Email: ResearchInstituteInquiries@CommonSpirit.org
Cleveland
Case Western Reserve University
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org
Cleveland Clinic Cancer Center/Fairview Hospital
Contact: Site Public Contact
Email: TaussigResearch@ccf.org
Cleveland Clinic Foundation
Contact: Site Public Contact
Email: TaussigResearch@ccf.org
Columbus
Columbus Oncology and Hematology Associates Inc
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Doctors Hospital
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Grant Medical Center
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Mount Carmel East Hospital
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Ohio State University Comprehensive Cancer Center
Contact: Site Public Contact
Email: Jamesline@osumc.edu
Riverside Methodist Hospital
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
The Mark H Zangmeister Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Dayton
Dayton Physician LLC - Englewood
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Miami Valley Hospital
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Miami Valley Hospital North
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Premier Blood and Cancer Center
Contact: Site Public Contact
Delaware
Delaware Health Center-Grady Cancer Center
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Grady Memorial Hospital
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Dublin
Columbus Oncology and Hematology Associates
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Dublin Methodist Hospital
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Findlay
Armes Family Cancer Center
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Franklin
Atrium Medical Center-Middletown Regional Hospital
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Dayton Physicians LLC-Atrium
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Greenville
Miami Valley Cancer Care and Infusion
Contact: Site Public Contact
Grove City
Zangmeister Center Grove City
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Kettering
Greater Dayton Cancer Center
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Kettering Medical Center
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Lancaster
Fairfield Medical Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Mansfield
OhioHealth Mansfield Hospital
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Marion
OhioHealth Marion General Hospital
Contact: Site Public Contact
Email: Jennifer.Sexton@ohiohealth.com
Marysville
Memorial Hospital
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Mayfield Heights
Hillcrest Hospital Cancer Center
Contact: Site Public Contact
Email: TaussigResearch@ccf.org
Mentor
UH Seidman Cancer Center at Lake Health Mentor Campus
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org
Middleburg Heights
UH Seidman Cancer Center at Southwest General Hospital
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org
Mount Vernon
Knox Community Hospital
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Newark
Licking Memorial Hospital
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Perrysburg
Mercy Health Perrysburg Cancer Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Portsmouth
Southern Ohio Medical Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Springfield
Springfield Regional Cancer Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Springfield Regional Medical Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Toledo
Mercy Health - Saint Anne Hospital
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Toledo Clinic Cancer Centers-Toledo
Contact: Site Public Contact
Troy
Upper Valley Medical Center
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Westerville
Saint Ann's Hospital
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
Youngstown
Saint Elizabeth Youngstown Hospital
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Zanesville
Genesis Healthcare System Cancer Care Center
Contact: Site Public Contact
Email: Jeffh@columbusccop.org
OK
Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Site Public Contact
Email: ou-clinical-trials@ouhsc.edu
OR
Newberg
Providence Newberg Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Ontario
Saint Alphonsus Cancer Care Center-Ontario
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Oregon City
Providence Willamette Falls Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Portland
Oregon Health and Science University
Contact: Site Public Contact
Email: trials@ohsu.edu
Providence Portland Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Providence Saint Vincent Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
PA
Allentown
Lehigh Valley Hospital-Cedar Crest
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Altoona
UPMC Altoona
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu
Bethlehem
Lehigh Valley Hospital - Muhlenberg
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Bryn Mawr
Bryn Mawr Hospital
Contact: Site Public Contact
Email: turzoe@mlhs.org
East Stroudsburg
Pocono Medical Center
Contact: Site Public Contact
Email: Morgan_M.Horton@lvhn.org
Erie
UPMC Hillman Cancer Center Erie
Contact: Site Public Contact
Email: haneydl@upmc.edu
Greensburg
UPMC Cancer Centers - Arnold Palmer Pavilion
Contact: Site Public Contact
Mechanicsburg
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Contact: Site Public Contact
Email: haneydl@upmc.edu
Media
Riddle Memorial Hospital
Contact: Site Public Contact
Email: turzoe@mlhs.org
Monroeville
UPMC Hillman Cancer Center - Monroeville
Contact: Site Public Contact
Email: haneydl@upmc.edu
Paoli
Paoli Memorial Hospital
Contact: Site Public Contact
Email: turzoe@mlhs.org
Philadelphia
Fox Chase Cancer Center
Contact: Site Public Contact
Pennsylvania Hospital
Contact: Site Public Contact
Email: PennCancerTrials@careboxhealth.com
Thomas Jefferson University Hospital
Contact: Site Public Contact
Email: ONCTrialNow@jefferson.edu
Pittsburgh
UPMC-Passavant Hospital
Contact: Site Public Contact
University of Pittsburgh Cancer Institute (UPCI)
Contact: Site Public Contact
Sayre
Guthrie Medical Group PC-Robert Packer Hospital
Contact: Site Public Contact
Willow Grove
Asplundh Cancer Pavilion
Contact: Site Public Contact
Email: ONCTrialNow@jefferson.edu
Wynnewood
Lankenau Medical Center
Contact: Site Public Contact
Email: turzoe@mlhs.org
PR
Bayamon
Puerto Rico Hematology Oncology Group
Contact: Site Public Contact
Manati
Doctors Cancer Center
Contact: Site Public Contact
San Juan
Centro Comprensivo de Cancer de UPR
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu
PROncology
Contact: Site Public Contact
Email: info@PRoncology.com
RI
Providence
Women and Infants Hospital
Contact: Site Public Contact
SC
Boiling Springs
Prisma Health Cancer Institute - Spartanburg
Contact: Site Public Contact
Columbia
Prisma Health Richland Hospital
Contact: Site Public Contact
Easley
Prisma Health Cancer Institute - Easley
Contact: Site Public Contact
Email: Kim.Williams3@prismahealth.org
Greenville
BI-LO Charities Children's Cancer Center
Contact: Site Public Contact
Prisma Health Cancer Institute - Butternut
Contact: Site Public Contact
Prisma Health Cancer Institute - Eastside
Contact: Site Public Contact
Prisma Health Cancer Institute - Faris
Contact: Site Public Contact
Greer
Prisma Health Cancer Institute - Greer
Contact: Site Public Contact
Seneca
Prisma Health Cancer Institute - Seneca
Contact: Site Public Contact
SD
Sioux Falls
Sanford Cancer Center Oncology Clinic
Contact: Site Public Contact
Email: OncologyClinicTrialsSF@sanfordhealth.org
Sanford USD Medical Center - Sioux Falls
Contact: Site Public Contact
Email: OncologyClinicalTrialsSF@SanfordHealth.org
TN
Nashville
Vanderbilt University/Ingram Cancer Center
Contact: Site Public Contact
TX
Abilene
Hendrick Medical Center
Contact: Site Public Contact
Houston
Houston Methodist Hospital
Contact: Site Public Contact
M D Anderson Cancer Center
Contact: Site Public Contact
Email: askmdanderson@mdanderson.org
VA
Charlottesville
University of Virginia Cancer Center
Contact: Site Public Contact
Email: uvacancertrials@hscmail.mcc.virginia.edu
Fairfax
Inova Schar Cancer Institute
Contact: Site Public Contact
Email: Stephanie.VanBebber@inova.org
Falls Church
Inova Fairfax Hospital
Contact: Site Public Contact
Email: Stephanie.VanBebber@inova.org
Richmond
VCU Massey Cancer Center at Stony Point
Contact: Site Public Contact
Email: ctoclinops@vcu.edu
Virginia Cancer Institute
Contact: Site Public Contact
Email: smoore@vacancer.com
Virginia Commonwealth University/Massey Cancer Center
Contact: Site Public Contact
Email: CTOclinops@vcu.edu
South Hill
VCU Community Memorial Health Center
Contact: Site Public Contact
Email: nemer.elmouallem@vcuhealth.org
WA
Edmonds
Swedish Cancer Institute-Edmonds
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Issaquah
Swedish Cancer Institute-Issaquah
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Renton
Valley Medical Center
Contact: Site Public Contact
Email: research@valleymed.org
Seattle
Swedish Medical Center-First Hill
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Yakima
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Contact: Site Public Contact
Email: Memorial-ClinicalTrials@yvmh.org
WI
Appleton
ThedaCare Regional Cancer Center
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
ThedaCare Regional Medical Center - Appleton
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
Ashland
Duluth Clinic Ashland
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org
Berlin
ThedaCare Cancer Care - Berlin
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
Burlington
Aurora Cancer Care-Southern Lakes VLCC
Contact: Site Public Contact
Email: ncorp@aurora.org
Eau Claire
Marshfield Medical Center-EC Cancer Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Germantown
Aurora Health Care Germantown Health Center
Contact: Site Public Contact
Email: ncorp@aurora.org
Grafton
Aurora Cancer Care-Grafton
Contact: Site Public Contact
Email: ncorp@aurora.org
Green Bay
Aurora BayCare Medical Center
Contact: Site Public Contact
Email: ncorp@aurora.org
Saint Vincent Hospital Cancer Center Green Bay
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Saint Vincent Hospital Cancer Center at Saint Mary's
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Janesville
Mercyhealth Hospital and Cancer Center - Janesville
Contact: Site Public Contact
Email: oncologyclinicaltrials@mhemail.org
Kenosha
Aurora Cancer Care-Kenosha South
Contact: Site Public Contact
Email: ncorp@aurora.org
La Crosse
Gundersen Lutheran Medical Center
Contact: Site Public Contact
Email: cancerctr@gundersenhealth.org
Madison
University of Wisconsin Carbone Cancer Center - University Hospital
Contact: Site Public Contact
Email: clinicaltrials@cancer.wisc.edu
Marinette
Aurora Bay Area Medical Group-Marinette
Contact: Site Public Contact
Email: ncorp@aurora.org
Marshfield
Marshfield Medical Center-Marshfield
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Milwaukee
Aurora Cancer Care-Milwaukee
Contact: Site Public Contact
Email: ncorp@aurora.org
Aurora Saint Luke's Medical Center
Contact: Site Public Contact
Email: ncorp@aurora.org
Aurora Sinai Medical Center
Contact: Site Public Contact
Email: ncorp@aurora.org
Minocqua
Marshfield Clinic-Minocqua Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Mukwonago
ProHealth D N Greenwald Center
Contact: Site Public Contact
Email: research.institute@phci.org
Neenah
ThedaCare Regional Medical Center - Neenah
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
New London
ThedaCare Cancer Care - New London
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
Oconomowoc
ProHealth Oconomowoc Memorial Hospital
Contact: Site Public Contact
Oconto Falls
Saint Vincent Hospital Cancer Center at Oconto Falls
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Oshkosh
ThedaCare Cancer Care - Oshkosh
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
Vince Lombardi Cancer Clinic - Oshkosh
Contact: Site Public Contact
Email: ncorp@aurora.org
Racine
Aurora Cancer Care-Racine
Contact: Site Public Contact
Email: ncorp@aurora.org
Shawano
ThedaCare Cancer Care - Shawano
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
Sheboygan
Saint Vincent Hospital Cancer Center at Sheboygan
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Vince Lombardi Cancer Clinic-Sheboygan
Contact: Site Public Contact
Email: ncorp@aurora.org
Stevens Point
Marshfield Medical Center-River Region at Stevens Point
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Sturgeon Bay
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Summit
Aurora Medical Center in Summit
Contact: Site Public Contact
Email: ncorp@aurora.org
Two Rivers
Vince Lombardi Cancer Clinic-Two Rivers
Contact: Site Public Contact
Email: ncorp@aurora.org
Waukesha
UW Cancer Center at ProHealth Care
Contact: Site Public Contact
Email: Chanda.miller@phci.org
Waupaca
ThedaCare Cancer Care - Waupaca
Contact: Site Public Contact
Email: ResearchDept@thedacare.org
Wauwatosa
Aurora Cancer Care-Milwaukee West
Contact: Site Public Contact
Email: ncorp@aurora.org
West Allis
Aurora West Allis Medical Center
Contact: Site Public Contact
Email: ncorp@aurora.org
Weston
Marshfield Medical Center - Weston
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
WV
Charleston
West Virginia University Charleston Division
Contact: Site Public Contact
Huntington
Edwards Comprehensive Cancer Center
Contact: Site Public Contact
Email: Christina.Cole@chhi.org
Morgantown
West Virginia University Healthcare
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu
PRIMARY OBJECTIVE: I. To register, allocate, and assign patients to ComboMATCH treatment trials. SECONDARY OBJECTIVES: I. To evaluate the rate of positive outcomes in defined cohorts within treatment trials of treatment combinations including targeted therapies for molecularly defined populations, and also in the subset of treatment trials where the treatments are supported by in vivo models. II. To perform quality control of the patients registered in the form of pathological confirmation of disease and sub-type to confirm diagnosis and treatment arm allocation. SECONDARY CORRELATIVE OBJECTIVES: I. Assess the concordance of the central molecular characterization of the pre-treatment biopsy samples with the genetic readouts from the Designated Laboratories (DLs) for patients enrolled on the ComboMATCH treatment trials. II. To assess how the registration diagnostic tumor mutation profile and pre-treatment biopsy profile compare to the circulating tumor-derived deoxyribonucleic acid (ctDNA) mutation profile from plasma. EXPLORATORY OBJECTIVE: I. Assess association between ComboMATCH treatment trials outcomes (positive or negative) with the type of rationale for the selected drug combinations and the type of rationale for the gene variant/combination for selection (e.g., whether the trial was based on targeted therapies for molecularly defined populations, those that were supported by in vivo models, and those that were supported by empiric clinical data). OUTLINE: REGISTRATION: Patients undergo tumor mutational screening of previously-collected tumor samples for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing. Patients who are 18 years or older and have biopsiable disease undergo a new biopsy for research purposes prior to initiating treatment on the ComboMATCH treatment trial. TREATMENT: Patients with mutations targeted to investigational combination therapies are assigned to 1 of 20 treatment subprotocols. EAY191-N4: Patients with RAS pathway mutant ovarian or endometrial cancer are randomized to 1 of 2 arms. ARM I: Patients receive selumetinib PO and olaparib PO on study. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as echocardiogram (ECHO) or multigated acquisition (MUGA), and computed tomography (CT) scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. ARM II: Patients receive selumetinib PO on study. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. EAY191-N2: Patients with inactivating or inferred inactivating NF1 alterations, and hormone receptor positive, HER2-negative metastatic breast cancer. Patients who are fulvestrant naive are assigned to Cohort I, while patients who are fulvestrant resistant are assigned to Cohort II. COHORT I: Patients are randomized to 1 of 2 arms. ARM I:Patients receive fulvestrant intramuscularly (IM) on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO twice daily (BID) on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, magnetic resonance imaging (MRI), or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study. ARM II: Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study. COHORT II: Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study. EAY191-E4: Patients with solid tumors who previously underwent taxane therapy. Patients receive nilotinib hydrochloride monohydrate PO twice daily (BID) on days 1-28 and paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression. EAY191-A3: Patients with KRAS/NRAS/BRAF mutated low-grade serous ovarian cancer (LGSOC) naive to MEK or CDK4/6 inhibitor therapy are randomized to either combination cohort 1 or monotherapy cohort 1. Patients with LGSOC who have received prior MEK inhibitor therapy are assigned to combination cohort 2. Patients with KRAS/NRAS/HRAS/non-V600E BRAF mutated pancreatic cancer are assigned to combination cohort 3. Patients with all other KRAS/NRAS/HRAS mutated tumor types (excluding LGSOC, non-small cell lung cancer, colorectal cancer, pancreatic, and melanoma) are assigned to combination cohort 4. COMBINATION COHORTS 1, 2, 3, 4: Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. MONOTHERAPY COHORT 1: Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. EAY191-S3: Patients with an activating AKT mutation solid tumor. Patients receive paclitaxel IV and ipatasertib PO on study. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up. EAY191-A6: Patients with RAS/RAF/MEK/ERK mutant biliary tract cancers are randomized to 1 of 2 arms. ARM 1: Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo echocardiogram (ECHO) and multigated acquisition scan (MUGA) during screening and on study, a CT with contrast, MRI, or a fludeoxyglucose F-18 positron emission tomography (FDG-PET) during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated. ARM 2: Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated. EAY191-E5: Patients are assigned to 1 of 2 cohorts. COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B. ARM A: Patients receive sotorasib PO once daily (QD) on days 1-28 and panitumumab intravenously IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C. ARM C: Patients receive combination therapy as in Arm A. EAY191-A2: Patients are assigned to 1 of 3 cohorts. COHORT 1: PARP-inhibitor naive patients are assigned to Arm A. ARM A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. COHORT 2: PARP-inhibitor naive patients are randomized to 1 of 2 arms. ARM B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. ARM C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. COHORT 3: PARP-inhibitor resistant patients are assigned to Arm D. ARM D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. EAY191-N5: Patients are randomized to 1 of 2 arms. ARM I: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. ARM II: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
Interactive content above is from the official study record on the National Cancer Institute website, cancer.gov.
ComboMATCH is a large precision medicine initiative led by the ECOG-ACRIN Cancer Research Group and National Cancer Institute through its National Clinical Trials Network. ComboMATCH includes several treatment trials led by the Alliance for Clinical Trials in Oncology, Childrenās Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network.